NovoLet® Surveillance Study on Using Human Insulin System in Indonesia
NCT ID: NCT01492153
Last Updated: 2017-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1981 participants
OBSERVATIONAL
2003-02-11
2006-09-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
NovoLet® Acceptance Study Within the Hospital Practise in Indonesia
NCT01492205
Observational Study With InnoLet® in Daily Clinical Practice
NCT01492959
Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical Practice
NCT01492166
Observational Study to Evaluate Safety and Efficacy of Insulin Therapy in Type 2 Diabetes Mellitus Subjects Failing on Oral Anti-diabetic Agents
NCT00715780
Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction
NCT01492218
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NovoLet® device
biphasic human insulin
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
isophane human insulin
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
human soluble insulin
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
biphasic human insulin
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
isophane human insulin
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
human soluble insulin
NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Type 2 diabetes mellitus
* Other types of diabetes mellitus (gestational, drug induced \[thiazide\] or metabolic syndrome-related)
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1457)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Jakarta, , Indonesia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NOPEN3-1886
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.